AU2009306114B2 - Vaccine compositions comprising a mutated factor H binding protein - Google Patents
Vaccine compositions comprising a mutated factor H binding protein Download PDFInfo
- Publication number
- AU2009306114B2 AU2009306114B2 AU2009306114A AU2009306114A AU2009306114B2 AU 2009306114 B2 AU2009306114 B2 AU 2009306114B2 AU 2009306114 A AU2009306114 A AU 2009306114A AU 2009306114 A AU2009306114 A AU 2009306114A AU 2009306114 B2 AU2009306114 B2 AU 2009306114B2
- Authority
- AU
- Australia
- Prior art keywords
- factor
- binding protein
- composition
- binding
- neisseria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101710186862 Factor H binding protein Proteins 0.000 title claims description 129
- 239000000203 mixture Substances 0.000 title claims description 69
- 229960005486 vaccine Drugs 0.000 title description 21
- 102000016550 Complement Factor H Human genes 0.000 claims description 73
- 108010053085 Complement Factor H Proteins 0.000 claims description 73
- 241000588650 Neisseria meningitidis Species 0.000 claims description 46
- 230000028993 immune response Effects 0.000 claims description 35
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 230000001681 protective effect Effects 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 201000009906 Meningitis Diseases 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 230000002163 immunogen Effects 0.000 claims description 11
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000002649 immunization Methods 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 241000588653 Neisseria Species 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940021993 prophylactic vaccine Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 43
- 230000003993 interaction Effects 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 21
- 102100032406 Cytosolic carboxypeptidase 6 Human genes 0.000 description 12
- 101000868785 Homo sapiens Cytosolic carboxypeptidase 6 Proteins 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 101710185445 Cytochrome c peroxidase, mitochondrial Proteins 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000036303 septic shock Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000002547 anomalous effect Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000037909 invasive meningococcal disease Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 208000037941 meningococcal disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 101710184994 Complement control protein Proteins 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- 102100025717 Cytosolic carboxypeptidase-like protein 5 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000932585 Homo sapiens Cytosolic carboxypeptidase-like protein 5 Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000255964 Pieridae Species 0.000 description 1
- 241000404883 Pisa Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 208000019880 recessive mitochondrial ataxia syndrome Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015275311A AU2015275311B2 (en) | 2008-10-25 | 2015-12-23 | Vaccine compositions comprising a mutated factor h binding protein |
| AU2017245320A AU2017245320B2 (en) | 2008-10-25 | 2017-10-10 | Vaccine compositions comprising a mutated factor h binding protein |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0819633.9A GB0819633D0 (en) | 2008-10-25 | 2008-10-25 | Composition |
| GB0819633.9 | 2008-10-25 | ||
| PCT/GB2009/051439 WO2010046715A1 (en) | 2008-10-25 | 2009-10-26 | Vaccine compositions comprising a mutated factor h binding protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015275311A Division AU2015275311B2 (en) | 2008-10-25 | 2015-12-23 | Vaccine compositions comprising a mutated factor h binding protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009306114A1 AU2009306114A1 (en) | 2010-04-29 |
| AU2009306114B2 true AU2009306114B2 (en) | 2015-10-01 |
Family
ID=40133849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009306114A Ceased AU2009306114B2 (en) | 2008-10-25 | 2009-10-26 | Vaccine compositions comprising a mutated factor H binding protein |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20120052092A1 (enExample) |
| EP (2) | EP3501534B1 (enExample) |
| JP (2) | JP5676458B2 (enExample) |
| KR (3) | KR20170000390A (enExample) |
| CN (2) | CN102245202A (enExample) |
| AU (1) | AU2009306114B2 (enExample) |
| BR (1) | BRPI0919926A2 (enExample) |
| CA (1) | CA2741619A1 (enExample) |
| CO (1) | CO6382140A2 (enExample) |
| DK (1) | DK3501534T5 (enExample) |
| ES (1) | ES2970878T3 (enExample) |
| FI (1) | FI3501534T3 (enExample) |
| GB (1) | GB0819633D0 (enExample) |
| HR (1) | HRP20240226T1 (enExample) |
| HU (1) | HUE065348T2 (enExample) |
| LT (1) | LT3501534T (enExample) |
| MX (1) | MX2011004322A (enExample) |
| NZ (2) | NZ592444A (enExample) |
| PL (1) | PL3501534T3 (enExample) |
| PT (1) | PT3501534T (enExample) |
| RU (1) | RU2559528C2 (enExample) |
| SI (1) | SI3501534T1 (enExample) |
| WO (1) | WO2010046715A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261339B1 (en) | 1998-05-01 | 2017-03-22 | GlaxoSmithKline Biologicals SA | Neisseria meningitidis antigens and compositions |
| DK2270173T3 (en) | 1999-05-19 | 2016-03-07 | Glaxosmithkline Biolog Sa | Neisserial combination compositions |
| DK1801219T3 (en) | 1999-10-29 | 2015-12-07 | Glaxosmithkline Biolog Sa | Neisseriale antigenic peptides. |
| EP2270031A3 (en) | 2000-02-28 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Heterologous expression of neisserial proteins |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| EP2265640B1 (en) | 2008-03-10 | 2015-11-04 | Children's Hospital & Research Center at Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
| BRPI1009828A2 (pt) | 2009-03-24 | 2019-03-12 | Novartis Ag | adjuvante de proteína de ligação de fator h meningocócica |
| AU2010242905B2 (en) | 2009-04-30 | 2014-10-23 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHbp) and methods of use |
| BR112012010531A2 (pt) * | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" |
| BR112012022669A2 (pt) * | 2010-03-10 | 2017-02-14 | Glaxosmithkline Biologicals Sa | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
| BR112012024348B1 (pt) | 2010-03-30 | 2022-11-08 | Children's Hospital & Research Center At Oakland | Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada |
| US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
| CA2861946A1 (en) | 2012-02-02 | 2013-08-08 | Novartis Ag | Promoters for increased protein expression in meningococcus |
| RU2644340C2 (ru) | 2012-06-14 | 2018-02-08 | Новартис Аг | Вакцины для менингококка серогруппы х |
| HK1205138A1 (en) | 2012-07-27 | 2015-12-11 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| WO2014140562A1 (en) * | 2013-03-14 | 2014-09-18 | Isis Innovation Limited | Immunogenic composition to neisseria |
| KR20160034401A (ko) | 2013-08-02 | 2016-03-29 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 비-천연적으로 발생하는 인자 h 결합 단백질(fhbp) 및 이의 사용 방법 |
| AU2015222121B2 (en) | 2014-02-28 | 2018-01-18 | Glaxosmithkline Biologicals Sa | Modified meningococcal fHbp polypeptides |
| CN119613509A (zh) | 2014-07-23 | 2025-03-14 | 奥克兰儿童医院及研究中心 | 因子h结合蛋白变体及其使用方法 |
| BR122023020102A2 (pt) * | 2014-08-20 | 2023-12-12 | Stichting Sanquin Bloedvoorziening | Anticorpos de potenciamento do fator h e seus usos |
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| KR20210119397A (ko) | 2018-12-21 | 2021-10-05 | 그리피스 유니버시티 | 면역 반응을 유도하기 위한 조성물, 방법 및 용도 |
| EP3997108A4 (en) * | 2019-07-08 | 2024-03-20 | Crapaud Bio, Inc. | METHODS OF PRODUCING AND USING LIPOOLIGOSACCHARIDE COMPOSITIONS AND VACCINES |
| CA3147638A1 (en) | 2019-07-17 | 2021-01-21 | Gemini Therapeutics Sub, Inc. | Factor h potentiating antibodies and uses thereof |
| JP2024507828A (ja) | 2021-02-19 | 2024-02-21 | サノフィ パスツール インコーポレイテッド | Ｂ群髄膜炎菌組換えワクチン |
| TW202423477A (zh) | 2022-08-03 | 2024-06-16 | 美商賽諾菲巴斯德公司 | 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006081259A2 (en) * | 2005-01-27 | 2006-08-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| WO2007060548A2 (en) * | 2005-11-25 | 2007-05-31 | Novartis Vaccines And Diagnostics Srl | Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4786592A (en) * | 1986-06-18 | 1988-11-22 | Scripps Clinic And Research Foundation | Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin |
| US5476784A (en) * | 1993-04-06 | 1995-12-19 | Rice; Peter A. | Gonococcal anti-idiotypic antibodies and methods and compositions using them |
| GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US20070253964A1 (en) * | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
| RU2450019C2 (ru) * | 2006-06-29 | 2012-05-10 | Новартис Аг | Полипептиды из neisseria meningitidis |
| NZ598458A (en) * | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
| BR112012024348B1 (pt) * | 2010-03-30 | 2022-11-08 | Children's Hospital & Research Center At Oakland | Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada |
-
2008
- 2008-10-25 GB GBGB0819633.9A patent/GB0819633D0/en not_active Ceased
-
2009
- 2009-10-26 HU HUE18209661A patent/HUE065348T2/hu unknown
- 2009-10-26 WO PCT/GB2009/051439 patent/WO2010046715A1/en not_active Ceased
- 2009-10-26 CN CN2009801480003A patent/CN102245202A/zh active Pending
- 2009-10-26 NZ NZ592444A patent/NZ592444A/xx unknown
- 2009-10-26 EP EP18209661.0A patent/EP3501534B1/en active Active
- 2009-10-26 EP EP09753188.3A patent/EP2355845B1/en not_active Not-in-force
- 2009-10-26 BR BRPI0919926A patent/BRPI0919926A2/pt not_active Application Discontinuation
- 2009-10-26 PT PT182096610T patent/PT3501534T/pt unknown
- 2009-10-26 PL PL18209661.0T patent/PL3501534T3/pl unknown
- 2009-10-26 RU RU2011120706/10A patent/RU2559528C2/ru not_active IP Right Cessation
- 2009-10-26 JP JP2011532725A patent/JP5676458B2/ja not_active Expired - Fee Related
- 2009-10-26 AU AU2009306114A patent/AU2009306114B2/en not_active Ceased
- 2009-10-26 CN CN201510119007.XA patent/CN105412920A/zh active Pending
- 2009-10-26 KR KR1020167035443A patent/KR20170000390A/ko not_active Ceased
- 2009-10-26 NZ NZ601538A patent/NZ601538A/en not_active IP Right Cessation
- 2009-10-26 US US13/125,957 patent/US20120052092A1/en not_active Abandoned
- 2009-10-26 ES ES18209661T patent/ES2970878T3/es active Active
- 2009-10-26 KR KR1020117011885A patent/KR20110092282A/ko not_active Ceased
- 2009-10-26 HR HRP20240226TT patent/HRP20240226T1/hr unknown
- 2009-10-26 CA CA2741619A patent/CA2741619A1/en not_active Abandoned
- 2009-10-26 MX MX2011004322A patent/MX2011004322A/es active IP Right Grant
- 2009-10-26 DK DK18209661.0T patent/DK3501534T5/da active
- 2009-10-26 LT LTEP18209661.0T patent/LT3501534T/lt unknown
- 2009-10-26 FI FIEP18209661.0T patent/FI3501534T3/fi active
- 2009-10-26 SI SI200932190T patent/SI3501534T1/sl unknown
- 2009-10-26 KR KR1020197002691A patent/KR20190011836A/ko not_active Ceased
-
2011
- 2011-05-05 CO CO11055224A patent/CO6382140A2/es not_active Application Discontinuation
-
2014
- 2014-12-25 JP JP2014261910A patent/JP6076326B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006081259A2 (en) * | 2005-01-27 | 2006-08-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| WO2007060548A2 (en) * | 2005-11-25 | 2007-05-31 | Novartis Vaccines And Diagnostics Srl | Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870 |
Non-Patent Citations (3)
| Title |
|---|
| BEERNINK PETER T ET AL: JOURNAL OF INFECTIOUS DISEASES (15 May 2007), vol. 195, no. 10, pages 1472-1479 * |
| GIULIANI et al; INFECTION AND IMMUNITY, Feb. 2005, Vol. 73, No. 2, p.1151-1160 * |
| MASIGNANI v ET AL: THE JOURNAL OF EXPERIMENTAL MEDICINE (17 March 2003), vol. 197, no. 6, pages 789-799 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009306114B2 (en) | Vaccine compositions comprising a mutated factor H binding protein | |
| CN102834410B (zh) | 改性的h因子结合蛋白（fhbp）及其使用方法 | |
| EP2265640A2 (en) | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use | |
| KR20000057575A (ko) | 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원 | |
| AU2017319218B2 (en) | Modified factor H binding protein | |
| AU2013304832B2 (en) | Neisseria meningitidis fHbp variant and its use for vaccination | |
| KR100509712B1 (ko) | 나이세리아 락토페린 결합 단백질 | |
| CN104072590B (zh) | 一种脑膜炎球菌抗原组合及其应用 | |
| AU2017245320B2 (en) | Vaccine compositions comprising a mutated factor h binding protein | |
| EP3077512B1 (en) | Immunogenic compositions and vaccines derived from bacterial surface receptor proteins | |
| US9913889B2 (en) | Immunogenic TP0751 fragments | |
| WO2014140562A1 (en) | Immunogenic composition to neisseria | |
| MXPA00001591A (en) | Neisseria lactoferrin binding protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |